Company: SMNR
Filing Date: 2025-08-15
Form Type: 10-Q
Source: 0001213900-25-077047
Chunk: 3

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-15
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
     2,062,500  
     206  
     (10,736,738) 
     (10,736,481)
  
    Net loss 
     -  
     -  
     -  
     -  
     (385,122) 
     (385,122)
  
    Subsequent measurement of ordinary shares subject to possible redemption (interest earned on trust account and extension deposit) 
     -  
     -  
     -  
     -  
     (20,704) 
     (20,704)
  
    Balance as of June 30, 2025 (Unaudited) 
     510,000  
    $51  
    $2,062,500  
    $206  
    $(11,142,564) 
    $(11,142,307)

    For the Three and Six Months Ended June 30, 2024 

    Class A Ordinary Shares  
    Class B Ordinary Shares  
    Accumulated  
    Shareholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Deficit  
    Equity Deficit 
  
    Balance as of December 31, 2023 (Audited) 
     510,000  
    $51  
    $2,062,500  
    $206  
    $(8,282,297) 
    $(8,282,040)
  
    Net income 
     -  
     -  
     -  
     -  
     264,330  
     264,330 
  
    Subsequent measurement of ordinary shares subject to possible redemption (interest earned on trust account and extension deposit) 
     -  
     -  
     -  
     -  
     (803,885) 
     (803,885)
  
    Balance as of March 31, 2024 (Unaudited) 
     510,000  
     51  
     2,062,500  
     206  
     (8,821,852) 
     (8,821,595)
  
    Net income 
     -  
     -  
     -  
     -  
     448,912